Ulcerative colitis and Crohn's disease are the principal forms of inflammatory bowel disease.
Both represent chronic inflammation of the gastrointestinal tract, which displays …

Background & Aims Therapeutic drug monitoring (TDM) is widely available for biologic
therapies in patients with inflammatory bowel disease (IBD). We reviewed current data and …

Objective We aimed to provide an evidence-supported update of the ECCO-ESPGHAN
guideline on the medical management of paediatric Crohn's disease [CD]. Methods We …

Background Anti-TNF drugs are effective treatments for the management of Crohn's disease
but treatment failure is common. We aimed to identify clinical and pharmacokinetic factors …

Crohn's disease is an idiopathic inflammatory disorder of unknown etiology with genetic,
immunologic, and environmental influences. The incidence of Crohn's disease has steadily …

Tumor necrosis factor-α (TNFα) antagonists have advanced the management of
inflammatory bowel diseases patients leading to an improvement of patient's quality of life …

Therapeutic drug monitoring (TDM), which involves measurement of drug or active
metabolite levels and anti-drug antibodies, is a promising strategy that can be used to …

Background & Aims It is not clear what serum levels of anti–tumor necrosis factor are
associated with reduced intestinal inflammation in patients with inflammatory bowel disease …

Background Infliximab has been found to be efficacious in the treatment of fistulas in the
setting of Crohn's disease, even though some patients do not benefit from therapy. Aim To …

The main goals of Ulcerative Colitis (UC) treatment are to both induce and maintain the
clinical and endoscopic remission of disease, reduce the incidence of complications such as …